Skip to content

Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04920474
Enrollment
99999999
Registered
2021-06-09
Start date
1991-07-31
Completion date
2030-07-31
Last updated
2023-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allogeneic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Cellular Therapy, Marrow Toxic Injury

Brief summary

The primary purpose of the Research Sample Repository is to make blood samples available for research studies related to histocompatibility and hematopoietic cell transplantation (HCT) or other cellular therapy. Representatives of participating centers and investigators or research groups may request access to research samples contained in the Research Sample Repository for the purpose of conducting research including: * investigating molecular explanations for histocompatibility or clinical outcomes through analysis of genomic, epigenetic, or other biomolecular data * evaluating the factors that affect transplant or cellular therapy outcome * studying the distribution of HLA tissue types in different populations * studying the success of transplantation, cellular therapies or supportive care in the management of marrow toxic injuries * performing de-linked (anonymous) research

Detailed description

Research samples will be accepted from the following four categories: * Hematopoietic Cell or other Cellular Therapy Donors * Cord Blood Units * Hematopoietic Cell Transplantation or other Cellular Therapy Recipients * Patients with Marrow Toxic Injury

Interventions

None listed

Sponsors

Center for International Blood and Marrow Transplant Research
Lead SponsorNETWORK

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Eligibility to participate in the Research Sample Repository Protocol: Hematopoietic Cell (HC) or Other Cellular Therapy Donors * Donors are eligible to participate in the Research Sample Repository if they have donated or are scheduled to donate HCs or cellular therapy products to an allogeneic recipient either by a marrow harvest or by apheresis. This includes adults with and without decision making capacity and children. * All donors registered on the National Marrow Donor Program (NMDP) Registry, regardless of whether they have been requested to donate a product for a patient, are eligible to participate in the Research Sample Repository. Cord Blood Units (CBUs) * Testable material from CBUs (Specimens) infused at treatment centers covered under the C. W. Bill Young Transplantation Program are eligible for inclusion in the Research Sample Repository. Material may be submitted by participating treatment centers, centralized laboratories and Cord Blood Banks. Hematopoietic Cell Transplantation or Other Cellular Therapy Recipients * All U.S. recipients of allogeneic or autologous HC transplants or cellular therapies are eligible to participate in the Research Sample Repository. This includes adults with and without decision making capacity and children. Patients with Marrow Toxic Injury * Any patient who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Treatment Network (RITN) is eligible to participate in the Research Sample Repository. This includes adults with and without decision-making capacity and children. * Eligible patients may have received support care only, growth factor support, hematopoietic stem cell transplant or other appropriate medical treatment for marrow toxic injury

Design outcomes

Primary

MeasureTime frame
To make blood samples available for research studies related to histocompatibility and HCT or other cellular therapypre-HCT (recipient) or pre-donation (donor)

Countries

United States

Contacts

Primary ContactAshley Spahn
RepositoryIRB@NMDP.ORG

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026